Log In
Print
BCIQ
Print
Print this Print this
 

Moxetumomab pasudotox (CAT-8015)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionMurine anti-CD22 antibody variable fragment fused to PE38
Molecular Target CD22
Mechanism of ActionBinds CD22
 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of Development
More More
 Archive Items are loading loading
Get a free BioCentury trial today